Peptide Schedule
Cortagen5 residuesAEDPGEach bubble = one amino acid. Size = residue mass. Color = chemical class.Cortagen
Benefits
About Cortagen
Cortagen is a synthetic tetrapeptide with the amino acid sequence Ala-Glu-Asp-Pro, designed as a simplified bioregulator based on the active components found in Cortexin. It was developed by Professor Vladimir Khavinson's research group as part of a broader program to create tissue-specific short peptides that can influence gene expression in target organs. In animal studies, Cortagen has shown tissue-specific activity for neural tissue. When added to organotypic cultures, it selectively stimulated the growth of explants from rat brain cortex but not from other organs. In a sciatic nerve transection model, intramuscular Cortagen injections increased nerve fiber growth rate by 27% and conduction velocity by 40% over a 10-day treatment period. Microarray analysis in mice revealed that a 5-day course of Cortagen affected the expression of 110 known genes across multiple functional categories. The peptide also demonstrates epigenetic activity, inducing selective deheterochromatinization — the decondensation of aged, silenced chromatin regions — which may reactivate repressed genes in older individuals. The evidence base consists almost entirely of Russian-language publications, animal studies, and in vitro work. No controlled human clinical trials have been published in international peer-reviewed journals.
Who Should Consider Cortagen
- Researchers studying peptide-DNA interactions and epigenetic regulation
- Preclinical investigators exploring nerve regeneration therapies
- Individuals interested in Khavinson bioregulator protocols for cognitive support
- Those exploring neuroprotective peptides as adjuncts to standard neurological care
How Cortagen Works
Cortagen's primary mechanism centers on direct interaction with DNA in target cells. Its small size (~416 Da) allows it to penetrate both cell and nuclear membranes. Once inside the nucleus, the tetrapeptide binds specific DNA sequences in promoter regions of genes related to neurotrophic signaling and cellular stress response. Microarray studies showed Cortagen modulated 110 known genes after a 5-day treatment course. At the epigenetic level, Cortagen induces selective deheterochromatinization of facultative heterochromatin without affecting constitutive pericentromeric heterochromatin. In neural tissue, the peptide upregulates neurotrophic factors (BDNF, NGF) and antioxidant enzymes (SOD, catalase) while reducing oxidative stress markers.
What to Expect
No well-documented acute effects in humans. Gene expression changes begin within the first few days based on animal models.
Continued gene expression modulation expected. Some users anecdotally report subtle improvements in mental clarity.
Full course completion. Animal studies suggest peak effects on nerve regeneration occur toward the end of treatment courses.
Effects from epigenetic remodeling may persist well beyond the active dosing period.
Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 5mg | Daily |
| Moderate | 10mg | Daily |
| Aggressive | 20mg | Daily |
Note: Cortagen (Ala-Glu-Asp-Pro) is a synthetic tetrapeptide bioregulator developed by Vladimir Khavinson. It was derived through directed synthesis based on amino acid analysis of Cortexin, a polypeptide extract from the cerebral cortex. Oral capsule — no reconstitution required. Standard protocols involve 10-30 day courses taken 2-3 times per year.
How to Inject Cortagen
Take capsules on an empty stomach, 15-30 minutes before a meal, with water. Standard protocols use 10-20 mg per day, either as a single morning dose or split into two doses. Avoid evening dosing due to potential mild stimulatory effects. A typical course lasts 10-30 days and is repeated 2-3 times per year.
Cycling Protocol
Standard Khavinson bioregulator protocol: 10-30 day courses taken 2-3 times per year with at least 3-month intervals between courses.
Pharmacokinetics
Source: Estimated from general tetrapeptide kinetics; no formal PK studies published for Cortagen
Loading the interactive decay curve.
Side Effects
Cortagen hasn't been evaluated in controlled human safety trials, so the side effect profile isn't well characterized. In nerve regeneration studies in rats, no adverse effects were reported. Theoretical concerns include mild gastrointestinal discomfort with oral administration, headache, and individual hypersensitivity reactions.
Contraindications
- Pregnancy and breastfeeding (no safety data available)
- Known hypersensitivity to any component of the formulation
- Children under 18 (insufficient pediatric data)
- Active malignancy (theoretical concern with gene expression modulation)
Drug Interactions
- No formal drug interaction studies have been published
- Theoretical additive effects when combined with other neuroprotective peptides (Cortexin, Cerebrolysin, Semax)
- Use caution with CNS-active medications
Storage & Stability
Molecular Profile
Related Peptides
References
- Elucidation of the effect of brain cortex tetrapeptide Cortagen on gene expression in mouse heart by microarrayPubMed 15159690
- Effect of tetrapeptide cortagen on regeneration of sciatic nervePubMed 11276314
- Cortexin and cortagen as correcting agents in brain ischemiaPubMed 21476278
- Tissue-specific effects of peptidesPubMed 11713572
- Neuroprotective effects of peptides bioregulators in people of various agePubMed 24738258